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Figure 6. a) Improved survival of MECP2-null mice following AAV9/MECP2 
infection but not following AAV9/GFP infection. b) Improving of body 
weight in mice from each group. 
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        INTRODUCTION 
 
Rett Syndrome (RTT) is an X-linked autism-spectrum disorder affecting 1 in every 10,000 female births. It is characterized by a normal development followed 
by an early neurological regression that severely affects motor, cognitive and communication skills. Over 95% of typical RTT is caused by mutations in the 
gene encoding the transcriptional modulator Methyl-CpG-Binding Protein 2 (MECP2) located in Xq282. MeCP2 acts by binding to methylated CG 
dinucleotides in some gene promoters, ultimately causing chromatin compactation leading to gene silencing.  Currently, there is not any curative therapy for 
Rett syndrome, and current management remains symptomatic. Exogenous delivery of MeCP2 following gene therapy approaches seems to be the only 
effective treatment to revert Rett phenotype, and some in vitro and in vivo studies using RTT mouse models have been performed in the last years. This 
project is a needed step in order to develop a treatment for human RTT patients, because it shows the possibility to revert the Rett-like phenotype through 
exogenous delivery of MeCP2 via AAV9 recombinant vectors in RTT mouse models. As MECP2-null mouse models’ phenotype mimics with high accuracy the 
Rett patients’ features, it is essential to develop great gene therapy procedures with low toxicity and improved survival using mouse models in order to 
create a treatment for the Rett syndrome affecting humans.  
 
        RESULTS 
 
• Neonatal CNS injection of AAV9/MECP2 results in widespread brain expression of 
exogenous administrated MeCP2.  
 
 
 
 
Figure 3. Detection of MeCP2 protein in wt mice 
and AAV9/MECP2-treated null mice but not in 
AAV9/GFP-treated null mice by western blot 
using actin as control. 
Figure 4 a) Quantification of transduction 
efficiency (as a proportion of DAPI-stained nuclei). 
b-e) Infected cells (Myc), Neurons (NeuN) and  % 
of infected cells (overlapping dots). 
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• AAV9-mediated neonatal delivery of 
MECP2 improves survival and body growth 
in MECP2-null mice. 
 
• Restored normal respiratory phenotype 
in MECP2-null mice following AAV9-
mediated neonatal delivery of MECP2.  
 
• AAV9-mediated neonatal delivery of 
MECP2 improves motor phenotype in 
MECP2-null mice. 
Animals 
 
3 groups (n=13): 
• WT not treated (control) 
• Mecp2tm1.1/Bird treated with 
AAV9-MECP2 (study group) 
• Mecp2tm1.1/Bird treated with 
AAV9-GFP (non-therapeutic 
control) 
 
      DISCUSSION 
 
This work shows the reversion of the Rett syndrome phenotype of MECP2-knockout mice 
following the exogenous delivery of MECP2 through direct brain administration of 
AAV9/MECP2 vector. A long-term expression of the exogenous protein is achieved and its 
expression pattern is similar to the endogenous one. Moreover, survival and body weight 
form MECP2-null mice are improved and phenotypic motor and respiratory abnormalities 
reverted. 
 
Figure 1. Vector design. The AAV vectors used in this study are AAV2 ITR-flanked genomes 
packaged into AAV9 serotype capsids with a truncated 229bp murine MECP2 promoter 
(MeP.) a) AAV9/MECP2 construct: it uses the human MECP2 coding region (MECP2_e1 mRNA 
isoform) with a C-terminal Myc epitope tag and the bovine growth hormone polyadenylation 
signal. b) AAV9/green fluorescent protein (GFP) using the SV40 polyadenylation signal.  
 
Figure 5. MeCP2 relative expression in brain samples 
from mice of each group. AAV9/GFP-treated null mice 
show no expression of MeCP2, whereas AAV9/MECP2-
treated mice recapitulate the endogenous expression 
up to 50%. 
EXPERIMENT DESIGN 
• AAV9/MECP2 infection recapitulates MeCP2 expression in CNS cells 
from MECP2-null mice 
 
Figure 8. a) Treadmill performance at two different speeds 
(10cm/s and 25cm/s) performed by mice from every group.    
b-d) Open field duration measurements (movement duration, 
mean velocity and total distance). Figure 7. Respiratory measures. a) apnea per minute. b) breathing 
frequency (measured as breaths/minute). 
 
Figure 2. Experimental plan: injection and phenotyping start. 
Mice receive at P0-2 direct bilateral injection of virus into the 
neurophil (4’8x1010vg/mouse). Phenotyping tests are carried 
out at w8-10. 
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